| Project/Area Number |
18K16108
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 54010:Hematology and medical oncology-related
|
|---|
| Research Institution | Teikyo University (2019)
Chiba University (2018) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | NKT細胞 / CD1d / 白血病 / iNKT細胞 / NK受容体 |
|---|
| Outline of Final Research Achievements |
Invariant NKT (iNKT) cells are generally known to recognize glycolipid presented by CD1d. iNKT cell recognition of CD1d-negative tumor cells is unknown, and direct cytotoxicity of iNKT cells toward CD1d-negative tumor cells remains controversial. Here we demonstrated that activated iNKT cells recognize leukemia cells in a CD1d-independent manner, however, still in a TCR-mediated way. We also showed that iNKT cell in vivo cytotoxicity for CD1d-negative leukemia cells in NOG mice. Therefore, adoptive iNKT cell therapy can be effective for leukemia independently of CD1d.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究はiNKT細胞がCD1d拘束性に糖脂質を認識すること以外にもCD1d非依存性に腫瘍認識機構を有することを明らかにした。このことからiNKT細胞養子免疫療法がCD1dの発現に依存せずヒト白血病に対して有効である可能性が示唆された。またiNKT細胞のCD1d非依存性細胞傷害活性には複数のNK受容体が関与していること、そしてその認識にはTCRが重要な役割を担っていることが明らかとなった。このことはiNKT細胞の新たなリガンドの発見につながる重要な示唆である。
|
